Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC.AGIO · Entity 4499 | Chief Legal Officer | June 18, 2026 | June 23, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AGIOS PHARMACEUTICALS, INC.
Report date June 18, 2026 · Filed June 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Performance share unitsSEC Table II · derivative / convertible security | Direct | 9,000 |
Reported balance
After 2026-06-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-18 · Exercise / conversion · Disposed 3,000 · Balance 9,000 F1: Each performance stock unit represents a contingent right to receive one share of the issuer's common stock. F2: Performance stock units were granted on March 1, 2025, and provide for the vesting of underlying shares upon the achievement of three specified clinical and research milestones established by the compensation & people committee, or board of directors, as applicable. The performance criteria for the specified research milestone was determined by the compensation & people committee to be met as of June 18, 2026. The shares related to such milestone will vest on December 31, 2027, subject to the recipient's continued service. |
| Restricted stock unitsSEC Table II · derivative / convertible security | Direct | 3,000 |
Reported balance
After 2026-06-18 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-18 · Grant · Acquired 3,000 · Balance 3,000 F3: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2: Performance stock units were granted on March 1, 2025, and provide for the vesting of underlying shares upon the achievement of three specified clinical and research milestones established by the compensation & people committee, or board of directors, as applicable. The performance criteria for the specified research milestone was determined by the compensation & people committee to be met as of June 18, 2026. The shares related to such milestone will vest on December 31, 2027, subject to the recipient's continued service. |
Filing footnotes · ownership attribution and instrument terms
F1: Each performance stock unit represents a contingent right to receive one share of the issuer's common stock.
F2: Performance stock units were granted on March 1, 2025, and provide for the vesting of underlying shares upon the achievement of three specified clinical and research milestones established by the compensation & people committee, or board of directors, as applicable. The performance criteria for the specified research milestone was determined by the compensation & people committee to be met as of June 18, 2026. The shares related to such milestone will vest on December 31, 2027, subject to the recipient's continued service.
F3: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 24, 2024 Filed Jan 24, 2024 21:25 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 1,708 | $21.64 | $36,961.12 |
DisclosureSEC source: 0001439222-24-000022 · wk-form4_1706131506.xml · nonDerivative · entry 2 Burns James William · CIK 0001900772 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 30,378 F1 · kind: Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated March 1, 2022. Read SEC document |
| January 20, 2024 Filed Jan 24, 2024 21:25 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionPerformance share units · Derivative | 5,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-24-000022 · wk-form4_1706131506.xml · derivative · entry 3 Burns James William · CIK 0001900772 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 5,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each performance share unit represents a contingent right to receive one share of the issuer's common stock. F3 · derivative.exercise_date: The PSUs were granted on March 1, 2022. The PSUs vest upon the achievement of a specified research milestone. The performance criteria for the specified research milestone was determined to have been met on January 20, 2024, resulting in the vesting of the PSUs. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F3 · derivative.expiration_date: The PSUs were granted on March 1, 2022. The PSUs vest upon the achievement of a specified research milestone. The performance criteria for the specified research milestone was determined to have been met on January 20, 2024, resulting in the vesting of the PSUs. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document |
| January 20, 2024 Filed Jan 24, 2024 21:25 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 5,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-24-000022 · wk-form4_1706131506.xml · nonDerivative · entry 1 Burns James William · CIK 0001900772 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 32,086 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 09, 2024 Filed Jan 9, 2024 21:25 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 1,163 | $22.99 | $26,737.37 |
DisclosureSEC source: 0001439222-24-000006 · wk-form4_1704835508.xml · nonDerivative · entry 2 Burns James William · CIK 0001900772 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,336 F2 · kind: Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated February 10, 2021. Read SEC document |
| January 05, 2024 Filed Jan 9, 2024 21:25 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionPerformance share units · Derivative | 3,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-24-000006 · wk-form4_1704835508.xml · derivative · entry 3 Burns James William · CIK 0001900772 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 3,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each performance share unit represents a contingent right to receive one share of the issuer's common stock. F4 · derivative.exercise_date: The PSUs were granted on February 10, 2021. The PSUs vest upon the achievement of a specified clinical milestone. The performance criteria for the specified clinical milestone was determined to have been met on January 5, 2024, resulting in the vesting of the PSUs. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F4 · derivative.expiration_date: The PSUs were granted on February 10, 2021. The PSUs vest upon the achievement of a specified clinical milestone. The performance criteria for the specified clinical milestone was determined to have been met on January 5, 2024, resulting in the vesting of the PSUs. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document |
| January 05, 2024 Filed Jan 9, 2024 21:25 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 3,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-24-000006 · wk-form4_1704835508.xml · nonDerivative · entry 1 Burns James William · CIK 0001900772 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,499 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 359 shares purchased through the Company's employee stock purchase plan. Read SEC document |
| August 17, 2023 Filed Aug 21, 2023 20:03 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 6,395 | $26.28 | $168,060.60 |
DisclosureSEC source: 0001439222-23-000131 · wk-form4_1692648215.xml · nonDerivative · entry 1 Burns James William · CIK 0001900772 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,890 F1 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $26.21 to $26.36. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| June 30, 2023 Filed Jun 30, 2023 20:09 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 1,707 | $28.36 | $48,410.52 |
DisclosureSEC source: 0001439222-23-000109 · wk-form4_1688155746.xml · nonDerivative · entry 2 Burns James William · CIK 0001900772 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 30,285 F1 · kind: Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. Read SEC document |
| June 28, 2023 Filed Jun 30, 2023 20:09 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionPerformance share units · Derivative | 5,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-23-000109 · wk-form4_1688155746.xml · derivative · entry 3 Burns James William · CIK 0001900772 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,750 Underlying: Common stock · 5,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each performance share unit represents a contingent right to receive one share of the issuer's common stock. F3 · derivative.exercise_date: The PSUs vest as to 50% of the underlying shares upon the achievement of a specified clinical milestone and as to 50% of the underlying shares upon the achievement of a specified research milestone. The performance criteria for the specified clinical milestone was determined to have been met on June 28, 2023, resulting in the vesting of the PSUs as to 50% of the underlying shares of common stock on that date. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F3 · derivative.expiration_date: The PSUs vest as to 50% of the underlying shares upon the achievement of a specified clinical milestone and as to 50% of the underlying shares upon the achievement of a specified research milestone. The performance criteria for the specified clinical milestone was determined to have been met on June 28, 2023, resulting in the vesting of the PSUs as to 50% of the underlying shares of common stock on that date. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document |
| June 28, 2023 Filed Jun 30, 2023 20:09 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 5,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-23-000109 · wk-form4_1688155746.xml · nonDerivative · entry 1 Burns James William · CIK 0001900772 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,992 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 03, 2023 Filed Mar 3, 2023 21:06 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Tax withholdingCommon stock | 1,129 | $25.02 | $28,247.58 |
DisclosureSEC source: 0001439222-23-000049 · wf-form4_167787758550061.xml · nonDerivative · entry 2 Burns James William · CIK 0001900772 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,242 Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 21:06 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionRestricted stock units · Derivative | 3,833 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-23-000049 · wf-form4_167787758550061.xml · derivative · entry 5 Burns James William · CIK 0001900772 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,667 Underlying: Common stock · 3,833 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F4 · derivative.exercise_date: The restricted stock units were granted on March 1, 2022. Beginning on March 1, 2023, the shares underlying the restricted stock units will vest in three equal annual installments. F4 · derivative.expiration_date: The restricted stock units were granted on March 1, 2022. Beginning on March 1, 2023, the shares underlying the restricted stock units will vest in three equal annual installments. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 21:06 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantStock options (right to buy) · Derivative | 44,000 | $0.00 Strike: $25.01 | $0.00 |
DisclosureSEC source: 0001439222-23-000049 · wf-form4_167787758550061.xml · derivative · entry 4 Burns James William · CIK 0001900772 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,000 Underlying: Common stock · 44,000 shares Expires 2033-03-01 F3 · derivative.exercise_date: This option was granted on March 1, 2023. The shares underlying this option vest as to 25% of the underlying shares on March 1, 2024, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 21:06 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantRestricted stock units · Derivative | 12,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-23-000049 · wf-form4_167787758550061.xml · derivative · entry 3 Burns James William · CIK 0001900772 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common stock · 12,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The restricted stock units were granted on March 1, 2023. Beginning on March 1, 2024, the shares underlying the restricted stock units will vest in three equal annual installments. F2 · derivative.expiration_date: The restricted stock units were granted on March 1, 2023. Beginning on March 1, 2024, the shares underlying the restricted stock units will vest in three equal annual installments. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 21:06 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 3,833 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-23-000049 · wf-form4_167787758550061.xml · nonDerivative · entry 1 Burns James William · CIK 0001900772 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,371 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 16, 2023 Filed Feb 16, 2023 21:04 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Tax withholdingCommon stock | 609 | $28.91 | $17,606.19 |
DisclosureSEC source: 0001439222-23-000025 · wf-form4_167658143694129.xml · nonDerivative · entry 2 Burns James William · CIK 0001900772 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,538 Read SEC document |
| February 14, 2023 Filed Feb 14, 2023 21:07 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Tax withholdingCommon stock | 643 | $28.44 | $18,286.92 |
DisclosureSEC source: 0001439222-23-000018 · wf-form4_167640884813599.xml · nonDerivative · entry 2 Burns James William · CIK 0001900772 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,409 Read SEC document |
| February 14, 2023 Filed Feb 16, 2023 21:04 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionRestricted stock units · Derivative | 1,738 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-23-000025 · wf-form4_167658143694129.xml · derivative · entry 3 Burns James William · CIK 0001900772 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 1,738 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The restricted stock units were granted on February 14, 2020. Beginning on February 14, 2021, the shares underlying the restricted stock units will vest in three equal annual installments. F2 · derivative.expiration_date: The restricted stock units were granted on February 14, 2020. Beginning on February 14, 2021, the shares underlying the restricted stock units will vest in three equal annual installments. Read SEC document |
| February 14, 2023 Filed Feb 16, 2023 21:04 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 1,738 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-23-000025 · wf-form4_167658143694129.xml · nonDerivative · entry 1 Burns James William · CIK 0001900772 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,147 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 10, 2023 Filed Feb 14, 2023 21:07 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionRestricted stock units · Derivative | 1,834 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-23-000018 · wf-form4_167640884813599.xml · derivative · entry 3 Burns James William · CIK 0001900772 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,833 Underlying: Common stock · 1,834 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The restricted stock units were granted on February 10, 2021. Beginning on February 10, 2022, the shares underlying the restricted stock units will vest in three equal annual installments. F2 · derivative.expiration_date: The restricted stock units were granted on February 10, 2021. Beginning on February 10, 2022, the shares underlying the restricted stock units will vest in three equal annual installments. Read SEC document |
| February 10, 2023 Filed Feb 14, 2023 21:07 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 1,834 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-23-000018 · wf-form4_167640884813599.xml · nonDerivative · entry 1 Burns James William · CIK 0001900772 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,052 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 28, 2022 Filed Dec 28, 2022 21:05 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Tax withholdingCommon stock | 2,597 | $28.48 | $73,962.56 |
DisclosureSEC source: 0001439222-22-000105 · wf-form4_167226150591374.xml · nonDerivative · entry 2 Burns James William · CIK 0001900772 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,218 Read SEC document |
| December 23, 2022 Filed Dec 28, 2022 21:05 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionRestricted stock units · Derivative | 8,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-22-000105 · wf-form4_167226150591374.xml · derivative · entry 3 Burns James William · CIK 0001900772 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 8,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F3 · derivative.exercise_date: The restricted stock units were granted on December 23, 2020. The shares underlying the restricted stock units will vest in full on December 23, 2022. F3 · derivative.expiration_date: The restricted stock units were granted on December 23, 2020. The shares underlying the restricted stock units will vest in full on December 23, 2022. Read SEC document |
| December 23, 2022 Filed Dec 28, 2022 21:05 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 8,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-22-000105 · wf-form4_167226150591374.xml · nonDerivative · entry 1 Burns James William · CIK 0001900772 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,815 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 272 shares purchased through the Company's employee stock purchase plan. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 21:09 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantStock options (right to buy) · Derivative | 41,000 | $0.00 Strike: $32.20 | $0.00 |
DisclosureSEC source: 0001439222-22-000026 · wf-form4_164634173010870.xml · derivative · entry 2 Burns James William · CIK 0001900772 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,000 Underlying: Common stock · 41,000 shares Expires 2032-03-01 F3 · derivative.exercise_date: This option was granted on March 1, 2022. The shares underlying this option vest as to 25% of the underlying shares on March 1, 2023, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 21:09 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantRestricted stock units · Derivative | 11,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-22-000026 · wf-form4_164634173010870.xml · derivative · entry 1 Burns James William · CIK 0001900772 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,500 Underlying: Common stock · 11,500 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The restricted stock units were granted on March 1, 2022. Beginning on March 1, 2023, the shares underlying the restricted stock units will vest in three equal annual installments. F2 · derivative.expiration_date: The restricted stock units were granted on March 1, 2022. Beginning on March 1, 2023, the shares underlying the restricted stock units will vest in three equal annual installments. Read SEC document |
| February 22, 2022 Filed Feb 23, 2022 21:10 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionRestricted stock units · Derivative | 724 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-22-000016 · wf-form4_164565059136535.xml · derivative · entry 3 Burns James William · CIK 0001900772 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 724 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The restricted stock units were granted on February 22, 2019. Beginning on February 22, 2020, the shares underlying the restricted stock units will vest in three equal annual installments. F2 · derivative.expiration_date: The restricted stock units were granted on February 22, 2019. Beginning on February 22, 2020, the shares underlying the restricted stock units will vest in three equal annual installments. Read SEC document |
| February 22, 2022 Filed Feb 23, 2022 21:10 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Tax withholdingCommon stock | 215 | $29.08 | $6,252.20 |
DisclosureSEC source: 0001439222-22-000016 · wf-form4_164565059136535.xml · nonDerivative · entry 2 Burns James William · CIK 0001900772 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,793 Read SEC document |
| February 22, 2022 Filed Feb 23, 2022 21:10 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 724 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-22-000016 · wf-form4_164565059136535.xml · nonDerivative · entry 1 Burns James William · CIK 0001900772 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,008 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2022 Filed Feb 16, 2022 22:01 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionRestricted stock units · Derivative | 5,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-22-000011 · wf-form4_164504886293133.xml · derivative · entry 5 Burns James William · CIK 0001900772 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 5,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F3 · derivative.exercise_date: The restricted stock units were granted on February 14, 2020. The shares underlying the restricted stock units will vest in full on February 14, 2022. F3 · derivative.expiration_date: The restricted stock units were granted on February 14, 2020. The shares underlying the restricted stock units will vest in full on February 14, 2022. Read SEC document |
| February 14, 2022 Filed Feb 16, 2022 22:01 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionRestricted stock units · Derivative | 1,738 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-22-000011 · wf-form4_164504886293133.xml · derivative · entry 4 Burns James William · CIK 0001900772 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,738 Underlying: Common stock · 1,738 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The restricted stock units were granted on February 14, 2020. Beginning on February 14, 2021, the shares underlying the restricted stock units will vest in three equal annual installments. F2 · derivative.expiration_date: The restricted stock units were granted on February 14, 2020. Beginning on February 14, 2021, the shares underlying the restricted stock units will vest in three equal annual installments. Read SEC document |
| February 14, 2022 Filed Feb 16, 2022 22:01 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Tax withholdingCommon stock | 2,155 | $30.50 | $65,727.50 |
DisclosureSEC source: 0001439222-22-000011 · wf-form4_164504886293133.xml · nonDerivative · entry 3 Burns James William · CIK 0001900772 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,284 Read SEC document |
| February 14, 2022 Filed Feb 16, 2022 22:01 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 5,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-22-000011 · wf-form4_164504886293133.xml · nonDerivative · entry 2 Burns James William · CIK 0001900772 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,439 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. Read SEC document |
| February 14, 2022 Filed Feb 16, 2022 22:01 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 1,738 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-22-000011 · wf-form4_164504886293133.xml · nonDerivative · entry 1 Burns James William · CIK 0001900772 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,189 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. Read SEC document |
| February 10, 2022 Filed Feb 14, 2022 21:06 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionRestricted stock units · Derivative | 1,833 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-22-000004 · wf-form4_164487278925642.xml · derivative · entry 3 Burns James William · CIK 0001900772 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,667 Underlying: Common stock · 1,833 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The restricted stock units were granted on February 10, 2021. Beginning on February 10, 2022, the shares underlying the restricted stock units will vest in three equal annual installments. F2 · derivative.expiration_date: The restricted stock units were granted on February 10, 2021. Beginning on February 10, 2022, the shares underlying the restricted stock units will vest in three equal annual installments. Read SEC document |
| February 10, 2022 Filed Feb 14, 2022 21:06 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Tax withholdingCommon stock | 643 | $31.43 | $20,206.28 |
DisclosureSEC source: 0001439222-22-000004 · wf-form4_164487278925642.xml · nonDerivative · entry 2 Burns James William · CIK 0001900772 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,451 Read SEC document |
| February 10, 2022 Filed Feb 14, 2022 21:06 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 1,833 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-22-000004 · wf-form4_164487278925642.xml · nonDerivative · entry 1 Burns James William · CIK 0001900772 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,094 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.